Search Result

Pathways Recommended:	NF-κB MAPK/ERK Pathway

Results for "

NF-κB pathways

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NF-κB (214) Adrenergic Receptor (1) AIM2 (2) Akt (22) AMPK (3) Amyloid-β (1) Androgen Receptor (1) Antibiotic (5) AP-1 (2) Apoptosis (73) Autophagy (14) Bacterial (21) Bcl-2 Family (4) c-Myc (3) Calcium Channel (3) Caspase (5) CCR (1) CDK (3) Chloride Channel (2) Cholinesterase (ChE) (1) COX (21) CXCR (2) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) DNA/RNA Synthesis (3) E1/E2/E3 Enzyme (4) Elastase (1) Endogenous Metabolite (19) Epigenetic Reader Domain (1) ERK (30) Estrogen Receptor/ERR (2) Eukaryotic Initiation Factor (eIF) (1) FAK (2) Ferroptosis (3) Fungal (6) Glucocorticoid Receptor (1) GLUT (2) Glutathione S-transferase (4) HBV (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (4) Histone Demethylase (1) Histone Methyltransferase (1) HIV (6) HSP (3) HSV (2) IAP (1) IKK (13) Influenza Virus (4) Insulin Receptor (2) Interleukin Related (14) IRAK (1) Isotope-Labeled Compounds (1) JAK (11) JNK (10) Keap1-Nrf2 (13) MAP4K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (3) MEK (10) mGluR (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) MMP (5) Molecular Glues (2) mTOR (3) MyD88 (3) Necroptosis (1) NO Synthase (22) NOD-like Receptor (NLR) (8) Opioid Receptor (1) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (37) PAK (1) Parasite (10) PERK (2) PGE synthase (2) Phosphatase (2) PI3K (9) PKA (1) PKC (2) Potassium Channel (2) PPAR (3) PROTACs (2) Proteasome (2) PTEN (1) Pyruvate Kinase (2) RANKL/RANK (3) Ras (1) Reactive Oxygen Species (14) SARS-CoV (2) Ser/Thr Protease (1) Sirtuin (1) Sodium Channel (12) STAT (10) STING (3) TGF-beta/Smad (2) TNF Receptor (24) Toll-like Receptor (TLR) (14) Topoisomerase (2) Tyrosinase (2) VEGFR (2) Virus Protease (2)
By Research Areas:	Cancer (142) Cardiovascular Disease (31) Endocrinology (5) Infection (42) Inflammation/Immunology (214) Metabolic Disease (27) Neurological Disease (31)
Oligonucleotides:	Emulsifiers (1)

304

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

163

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

NF-κB-IN-1 2 Publications Verification	IKK	Cancer
NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .

NF-κB-IN-11	NF-κB	Inflammation/Immunology
NF-κB-IN-11 (Compound 3i) is a *NF-κB* inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .

NF-κB-IN-4	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated *NF-κB* pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .

TNF-α (31-45), human 5 Publications Verification	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology Cancer
TNF-α (31-45), human is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

Akt/NF-κB/JNK-IN-1	Akt NF-κB JNK TNF Receptor COX	Inflammation/Immunology
Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, *NF-κB* and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC₅₀ of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .

NF-κB/PON1-IN-1	NF-κB Reactive Oxygen Species	Cancer
NF-κB/PON1-IN-1 (Compound 16) is a *NF-κB/PON1* pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC₅₀ = 45.76 µM) and hepatoprotective activities .

TLR4/NF-κB/MAPK-IN-1	NF-κB p38 MAPK Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology
TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.

Multi-target Pt	NF-κB IKK	Cancer
Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .

NF-κB-IN-10	NF-κB	Cardiovascular Disease
NF-κB-IN-10 (compound E1) is an *NF-κB* inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating *Nrf2/NF-κB* signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .

NF-κB-IN-16	NF-κB Apoptosis	Cancer
NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of *NF-κB* inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .

TNF-α (31-45), human TFA	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology
TNF-α (31-45), human TFA is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

NF-κB/MAPK-IN-1	NF-κB p38 MAPK NO Synthase COX	Inflammation/Immunology
NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of *NF-κB* and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC₅₀ of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .

NBD-2	NF-κB	Inflammation/Immunology Cancer
NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the *NF-κB* signaling pathway. NBD-2 specifically inhibits the typical *NF-κB* signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to *NF-κB* signaling pathway, including autoimmune diseases, cancer, etc .

Glucocorticoid receptor/NF-κB modulator-1	Glucocorticoid Receptor NF-κB	Inflammation/Immunology
Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .

Akt/NF-κB/MAPK-IN-1	p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX	Others
Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC₅₀=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .

NF-κB-IN-14	NF-κB Toll-like Receptor (TLR)	Inflammation/Immunology
NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC₅₀: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the *NF-κB* signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .

NF-κB-IN-6	NF-κB	Inflammation/Immunology
NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing *NF-κB* signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC₅₀ of 23.1 μM .

Asperbisabolane L	NF-κB	Inflammation/Immunology
Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the *NF-κB*-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .

Echinulin Echinuline	NF-κB	Inflammation/Immunology
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to *NF-κB* activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent .

Salixteroside D	p38 MAPK NF-κB	Inflammation/Immunology
Salixteroside D is a salicin derivative, that exhibits anti-inflammatory activity through inhibition of MAPK and NF-κB signaling pathways .

Neocryptotanshinone	NF-κB NO Synthase	Inflammation/Immunology
Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza, inhibits lipopolysaccharide-induced inflammation by suppression of *NF-κB* and iNOS signaling pathways .

Lucyoside B	NF-κB	Inflammation/Immunology
Lucyoside B inhibits the production of inflammatory mediators via both *NF-κB* and activator protein-1 pathways in activated macrophages .

Bardoxolone methyl 25+ Cited Publications RTA 402; NSC 713200; CDDO Methyl ester	Keap1-Nrf2 Autophagy Apoptosis Ferroptosis	Cancer
Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the Nrf2 pathway and an inhibitor of the *NF-κB* pathway.

Ganoderterpene A	p38 MAPK	Neurological Disease
Ganoderterpene A attenuates LPS-induced inflammation and apoptosis via suppressing MAPK and TLR-4/NF-κB pathways in BV-2 cells.

APC0576	NF-κB	Inflammation/Immunology
APC0576 is an inhibitor for the activation of *NF-κB* signaling pathway, and inhibits the activation of NF-κB depedent gene (IC₅₀ is 1.0 μM for β-gal). APC0576 inhibits IL-1-induced chemokines release, and can be used in research about pathological endothelial cell activation releted diseases .

Chitosan oligosaccharide 4 Publications Verification COS	AMPK Endogenous Metabolite	Metabolic Disease Cancer
Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including *NF-κB* and MAPK pathways.

Anti-inflammatory agent 7	p38 MAPK NF-κB	Inflammation/Immunology
Anti-inflammatory agent 7 inhibits proinflammatory cytokines by blocking the *NF-κB/MAPK* signaling pathway in LPS-treated RAW 264.7 cells as well as mice.

Anti-inflammatory agent 48	NF-κB	Inflammation/Immunology
Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the *NF-κB* signaling pathway and activating HO-1 expression .

Hentriacontane	NF-κB Bacterial	Infection Inflammation/Immunology Cancer
Hentriacontane is a long-chain alkane. Hentriacontane exerts anti-inflammatory effects by inhibiting the *NF-κB* pathway. Hentriacontane has anti-inflammatory, antitumor and antibacterial activities .

Geranylgeraniol	NF-κB	Inflammation/Immunology
Geranylgeraniol is an orally acitve vitamin K₂ sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets *NF-kB* signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .

Inotilone	MMP NF-κB	Cancer
Inotilone is an inhibitor of matrix metalloproteinase MMP-2 and MMP-9, to against metastatic in lung cancer cells. Inotilone enhances the activity of the antioxidant enzymes to support its anti-metastatic activity. Inotilone also inhibits IκBα phosphorylation and NFκB p65 nuclear translocation, involving in FAK, PI3K/AKT, MAPKs and NFκB pathways .

MHY884	Tyrosinase NF-κB	Inflammation/Immunology
MHY884 is a tyrosinase inhibitor that suppresses UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress. MHY884 suppresses oxidative stress in the melanoma cells and attenuates UVB-induced oxidative stress, resulting in reduced NF-κB activity in irradiated mice. MHY884 is promising for research of UVB-induced skin damage .

Stachydrine 4 Publications Verification	NF-κB Endogenous Metabolite	Cardiovascular Disease Cancer
Stachydrine is a major constituent of Chinese herb leonurus heterophyllus sweet used to promote blood circulation and dispel blood stasis. Stachydrine can inhibit the *NF-κB* signal pathway.

Engeletin 3 Publications Verification	NF-κB	Infection Inflammation/Immunology
Engeletin is a flavanonol glycoside isolated from Smilax glabra Roxb. , inhibits *NF-κB* signaling-pathway activation, and possesses anti-inflammatory, analgesic, diuresis, detumescence, and antibiosis effects.

Karacoline	NF-κB	Endocrinology
Karacoline, a diterpene alkaloid found in the plant Aconitum kusnezoffii, reduces degradation of the extracellular matrix (ECM) in intervertebral disc degeneration (IDD) via the NF-κB signaling pathway .

COX-2-IN-48	COX NF-κB NO Synthase	Inflammation/Immunology
COX-2-IN-48 (5-25), a COX-2 inhibitor with an IC₅₀ of 51.7 nM for human COX-2, exerts anti-inflammatory and analgesic effects in various rodent models by inhibiting *NF-κB* pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, the phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS .

Stachydrine hydrochloride 4 Publications Verification	NF-κB Endogenous Metabolite	Cardiovascular Disease Cancer
Stachydrine hydrochloride is the major active constituent of Leonurus artemisia, which is a potential therapy for cardiovascular diseases . Stachydrine can inhibit the *NF-κB* signal pathway. Anti-hypertrophic activities .

Okanin 1 Publications Verification	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the *TLR4/NF-κB* signaling pathways .

Asperuloside 2 Publications Verification	NO Synthase	Metabolic Disease Inflammation/Immunology
Asperuloside is an iridoid isolated from Hedyotis diffusa, with anti-inflammatory activity. Asperuloside inhibits inducible nitric oxide synthase (iNOS), suppresses NF-κB and MAPK signaling pathways .

TNF-α-IN-11	TNF Receptor Caspase NF-κB	Inflammation/Immunology
TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor with a K_D value of 12.06 μM. TNF-α-IN-11 binds to TNF-α and blocks the activation of TNF-α-trigged caspase and *NF-κB* signaling pathway. TNF-α-IN-11 inhibits the phosphorylation of IκBα, as well as the nuclear translocation of NF κB p65. TNF-α-IN-11 can be used for research of TNF-α-mediated autoimmune diseases .

Kaempferol-3-O-glucorhamnoside	p38 MAPK NF-κB	Inflammation/Immunology
Kaempferol-3-O-glucorhamnoside, a flavonoid derived from plant Thesium chinense Turcz, inhibits inflammatory responses via MAPK and NF-κB pathways in vitro and in vivo .

2,5-Dihydroxyacetophenone	ERK NF-κB	Inflammation/Immunology
2,5-Dihydroxyacetophenone, isolated from Rehmannia glutinosa, inhibits the production of inflammatory mediators in activated macrophages by blocking the ERK1/2 and *NF-κB* signaling pathways .

WAY-169916	Estrogen Receptor/ERR NF-κB	Inflammation/Immunology
WAY-169916 is a pathway-selective ligand of ER (estrogen receptor) that acts by inhibiting NF-kB transcriptional activity. WAY-169916 has potent anti-inflammatory effect .

Streptazolin	Antibiotic	Infection Inflammation/Immunology
Streptazolin is an antibiotic. Streptazolin increases bacterial killing and elaboration of immunostimulatory cytokines by macrophages in vitro. Streptazolin stimulates the macrophage NF-κB pathway via PI3K signaling .

Goshonoside F5	NF-κB	Inflammation/Immunology
Goshonoside F5 can be isolated from the unripe fruits of Rubus chingii. Goshonoside F5 has anti-inflammatory activity, and inhibits NF-κB and MAPK signaling pathway .

Deguelin 5+ Cited Publications (-)-Deguelin; (-)-cis-Deguelin	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

Cat. No.	Product Name

HY-L014

NF-κB Signaling Compound Library

889 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 889 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

HY-L103

Anti-Colorectal Cancer Compound Library

1,725 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,725 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L124

Anti-Prostate Cancer Compound Library

2,449 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2,449 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library

2,123 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,123 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Fluorescent Dye

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

Cat. No.	Product Name	Type

HY-W042416

N,N-Dimethylacetamide 1 Publications Verification DMAc	Co-solvents
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the *NF-κB* signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-W042416R

N,N-Dimethylacetamide (Standard)

Co-solvents

N,N-Dimethylacetamide (Standard) is the analytical standard of N,N-Dimethylacetamide. This product is intended for research and analytical applications. N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1860

TNF-α (31-45), human 5 Publications Verification	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology Cancer
TNF-α (31-45), human is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P1259A

PR-39 TFA	Proteasome Bacterial	Inflammation/Immunology
PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P1098

Ac2-26 4 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-P1098A

Ac2-26 TFA 4 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-100538A

DTP3 TFA 1 Publications Verification	DNA/RNA Synthesis JNK	Cancer
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-P1860A

TNF-α (31-45), human TFA	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology
TNF-α (31-45), human TFA is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P10469

NBD-2	NF-κB	Inflammation/Immunology Cancer
NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the *NF-κB* signaling pathway. NBD-2 specifically inhibits the typical *NF-κB* signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to *NF-κB* signaling pathway, including autoimmune diseases, cancer, etc .

HY-P10399

KGYY15 Mouse KGYY15; KGYY15 peptide	TNF Receptor	Metabolic Disease
KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC₅₀ of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM .

HY-P1259

PR-39	Proteasome Bacterial	Inflammation/Immunology
PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P10350

PapRIV	NF-κB	Neurological Disease Inflammation/Immunology
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an *NF-κB*-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .

HY-P2036A

FSL-1 TFA 3 Publications Verification	Toll-like Receptor (TLR) MMP HSV Antibiotic	Infection
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection . FSL-1 TFA induces MMP-9 production through TLR2 and *NF-κB/AP-1* signaling pathways in monocytic THP-1 cells .

HY-P10349

Pap12-6	Bacterial	Infection Inflammation/Immunology
Pap12-6 is a 12-mer peptide derived from the antimicrobial peptide Papiliocin of yellow butterfly larva. Pap12-6 kills bacteria by penetrating and disrupting their membranes, exhibiting strong antibacterial activity. Pap12-6 exerts its anti-inflammatory effects through the TLR4-mediated *NF-κB* signaling pathway .

HY-P2114

IT9302	Peptides	Cancer
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .

Cat. No.	Product Name	Target	Research Area

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

Cat. No.	Product Name	Chemical Structure

HY-113439S

12-HETE-d8
12-HETE-d₈ is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway[1].12-HETE has both anti-thrombotic and pro-thrombotic effects[2]. 12-HETE is a neuromodulator[3].

HY-B0185AS

Lidocaine-d10 hydrochloride

Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-B0185S1

Lidocaine-d10

Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-12383S

Pelubiprofen-13C,d3

Pelubiprofen- ¹³C,d₃ is the ¹³C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects[1].

HY-B0185S

Lidocaine-d10 N-Oxide

N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-B0185AS1

Lidocaine-d6 hydrochloride

Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

HY-113509S

Lipoxin A4-d5

Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

Cat. No.	Product Name		Classification

HY-N2041

Myristic acid 3 Publications Verification		Emulsifiers
Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the *NF-κB* pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NF-κB pathways

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products